FTSE 100 today: U.K. stocks dip amid tariff worries; pound holds above $1.36

European stocks, including the FTSE 100, opened lower amid intensified trade uncertainty as the U.S. prepares to announce new tariffs ranging from 10% to 70% effective August 1st. Concurrently, UK Finance Minister Rachel Reeves plans a significant pension system overhaul, while homebuilder MJ Gleeson issued its second profit warning citing a weak housing market and increased costs, leading to a CEO departure. In contrast, AstraZeneca received EU approval for its Imfinzi cancer drug for certain bladder cancer forms, expanding its market reach.

Analysis

European equity markets are exhibiting weakness, with the FTSE 100, DAX, and CAC 40 declining by 0.3%, 0.2%, and 0.8% respectively, amid heightened uncertainty over impending U.S. trade tariffs slated to range from 10% to 70%. This macroeconomic pressure in the U.K. is coupled with domestic policy ambiguity, as the government plans a significant pension system overhaul to be detailed on July 15. At the corporate level, there is a clear divergence in performance. The U.K. housing sector is showing signs of significant stress, underscored by homebuilder MJ Gleeson's second profit warning in a month, which it attributes to a weak housing market, stagnant prices, and increased costs, leading to the departure of the Gleeson Homes unit CEO. Conversely, the pharmaceutical sector shows resilience, with AstraZeneca receiving a positive catalyst through EU regulatory approval for its cancer drug Imfinzi, thereby expanding the drug's addressable market and reinforcing its growth trajectory.

Key Decisions for Investors

• Given the broad market risk from impending tariffs, consider reducing exposure to European indices or implementing hedging strategies until there is more clarity on the U.S. trade policy.
• The second profit warning and CEO departure at MJ Gleeson is a strong negative signal for the UK homebuilding sector; investors should re-evaluate their positions in UK homebuilders and suppliers for similar signs of margin compression and weak demand.
• AstraZeneca's EU approval for Imfinzi provides a positive, company-specific catalyst that could offer a defensive position amid market turmoil, making it a candidate for accumulation on any broader market weakness.